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Abstract
Background: We aimed to determine the incidence of Hepatitis C (HCV) infection among HIV-infected men who
have sex with men (MSM) attending a Sexual Health Centre.
Methods: A retrospective cohort study was carried out among HIV-infected MSM seen at least once between
February 2002 and March 2010. The analysis was restricted to MSM who had had a negative HCV antibody test at
least 6 months after their diagnosis for HIV. Duration of follow up was taken from the date of HIV diagnosis to the
first positive or last negative HCV antibody test.
Results: During the time 1445 HIV-infected men attended the clinic of whom 1065 (74%) were MSM. Of these, 869
(82%) were tested for HCV at any time after HIV diagnosis. Of these 869, 69% (620) tested HCV negative at least 6
months after their HIV diagnosis. These 620 men had a mean age of 34 years (range 17-72) at HIV diagnosis and a
total of 4,359 person years (PY) of follow up. There were 40 incident cases of HCV, of which 16 were in injecting
drug users (IDU) and 24 in non-IDU. The overall incidence of HCV among HIV-infected MSM was 0.9/100 PY (95%
CI 0.6-1.2). The incidence among HIV-infected IDU was 4.7/100 PY (95% CI 2.7-7.5) while the incidence among HIV-
infected non-IDU was 0.6/100 PY (95% CI 0.4-0.8) (hazard ratio of 8.7 and 95% CI 4.6-16.6, P < 0.001).
The majority (78%) were tested for HCV because they developed abnormal liver transaminases (n = 31) or hepatitis
symptoms (n = 2), while others (n = 7) were identified through routine HCV testing.
Conclusion: A considerable proportion of HIV-positive MSM who did not inject drugs contracted HCV, presumably
via sexual transmission and the main trigger for investigation was abnormal liver transaminases.
Background
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sas i g n i f i c a n th e a l t h
issue, particularly among individuals with HIV infection
[1,2]. Co-infection with both HIV and HCV has been
associated with more rapid progression to HCV-related
liver disease, and increases the risk for cirrhosis and
liver cancer [2,3]. Hepatitis C is a major cause of hospi-
tal admissions and is a leading cause of death among
HIV-infected persons [4].
Hepatitis C infection is transmitted mainly by parent-
eral exposure, particularly in IDU [5]. It remains unclear
whether HCV is transmitted sexually between men, and
recently reviewed studies give conflicting results [6-13].
Those studies that support sexual transmission among
men having sex with men (MSM) [6-10] describe multi-
ple sex partners and other sexual practices as risks for
HCV transmission. A recent study in Sydney, Australia
[10] described possible sexual transmission of HCV in
HIV-negative MSM who did not use injecting drugs but
not among a small cohort of HIV-positive MSM.
Recently a number of bodies have recommended
screening for HCV among MSM with HIV, even in the
absence of any known risk factors for HCV infection
[14]. Our large sample size and existing risk factor data
allow us to generate tight confidence intervals around
HCV transmission among MSM with HIV. We therefore
carried out a retrospective cohort study to determine
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those who did not inject drugs.
Methods
This was a retrospective cohort study of MSM with HIV
infection. Individuals were eligible for the cohort if they
were seen at least once at Melbourne Sexual Health
Centre’s (MSHC) HIV clinic between February 2002 and
March 2010, and were negative for HCV antibodies at
least 6 months after the date of their HIV diagnosis.
This 6 month period was chosen because HCV antibo-
dies develop in the majority of infected patients within
6 months of infection [15,16]. Individuals who tested
positive for HCV antibodies at their first HCV antibody
test were excluded from the cohort analysis because
they could not be confirmed as incident cases. For indi-
viduals who tested negative for HCV antibodies at their
last test, follow up was from the date of their HIV diag-
nosis to the time of their last HCV test. For individuals
who tested HCV antibody positive, but who had a pre-
vious negative HCV antibody test, the follow up time
was taken from the time of their HIV diagnosis to the
time of their first positive HCV antibody test.
Risk factor data were extracted from the centre’s com-
puter database: Clinical Practice Management System
(CPMS). Risk factor data include both MSM without
IDU or MSM with IDU. Laboratory testing data for
H C Va n t i b o d yw e r ee x t r a c t e df r o mt h ec o m p u t e r i s e d
records of the Victorian Infectious Diseases Laboratory
(VIDRL). The medical records of incident cases of HCV
were reviewed by DG and TR to determine the reasons
for the HCV test and also to carefully ascertain if there
was any record of IDU that may have been missed from
routinely collected risk factors.
Routine annual screening for HCV began in 2008 for
MSM with HIV [17]. The same laboratory (VIDRL) has
been used by the clinic since 1992. Hepatitis C antibo-
dies were analyzed by enzyme immunoassay (EIA)
(Murex anti-HCV version 4.0, Abbott Diagnostics,
Abbott Park, Illinois, USA) and each positive result was
subjected to supplementary testing with the Bio-Rad
EIA (Bio-Rad Laboratories, Hercules, California, USA).
Subsequently, HCV positive cases were tested for HCV
RNA using the Cobas Amplicor
® version 2 polymerase
chain reaction (PCR) assay (Roche Diagnostics, Branch-
burg, NJ, USA).
The data collected in all three sources were merged
and analysed using the Statistical Package for Social
Sciences (SPSS) We calculated the incidence of HCV
per 100 person years and 95% confidence intervals for
all MSM, MSM who reported ever IDU and MSM with-
out a history of IDU. Hazard ratios and 95% confidence
intervals were calculated to compare incidence between
MSM who reported ever IDU and MSM without a
history of IDU. A Kaplan-Meier curve was generated to
illustrate the time to HCV acquisition for MSM who
reported ever IDU and MSM without a history of IDU
separately and the log rank method was used to com-
pare these two groups. Ethics clearance was obtained
from the ethics committee at the Alfred Hospital.
Results
There were 1445 HIV infected males seen at least once
at MSHC during the eight year period. Of these 1065
(74%) were MSM and of these 869 (82%) were tested
for HCV at any time after HIV diagnosis. Of these
869, we excluded 180 HCV-negatives because their
last HCV test was less than 6 months after their first
HIV positive test (figure 1). We also excluded 69 HCV
positive cases (41 non-IDU and 28 IDU) because they
had HCV at the time of or before their HIV diagnosis
(n = 47) or they did not have a negative HCV test
before their first positive HCV test (n = 22). Therefore
620 MSM with a HCV antibody negative test more
than 6 months after their HIV diagnosis were included
in this cohort.
Total HIV infected males = 1445 
HIV infected MSM =1065 
HIV infected MSM investigated for HCV=869 
Non MSM= 380 
Not investigated for 
HCV = 196 
HCV positive 
109 
HCV negative 
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First test 
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Figure 1 Cohort of HIV positive MSM in identifying hepatitis C
incident cases.
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34 years (range 17-72), 434 (70%) were Australian born
and 39 (6%) had ever injected drugs. The median CD4
count of the cohort on their last visit was 566 cells/mm
3
(inter quartile range 402 to 734 cells/mm
3) and 342 (73%)
had a HIV-VL of less than 50 copies/ml. Basic population
characteristics of the cohort are given in table 1.
There were 4359 person years (PY) of follow up during
which, 40 individuals developed HCV, with an incidence
of 0.9/100 PY (95% CI 0.6-1.2). Sixteen cases occurred in
those who had ever IDU (341 PY of follow up) with an
incidence of 4.7/100 PY (95% CI 2.7-7.5) and 24 cases
occurred in those who had never IDU (4018 PY) with an
incidence of 0.6/100 PY (95% CI 0.4-0.8). None of the
cases had documented evidence of tattoos or blood trans-
fusions. The incidence of HCV was significantly higher
among those with a history of ever injecting drugs (HR =
8.7; 95% CI 4.6-16.6, P < 0.001). Those born in Australia
compared to those born in overseas were not at greater
risk of acquiring HCV (HR 1.41, 95% CI: 0.65-3.09, P =
0.32). Individuals 35 years and older were not at greater
risk of HCV infection compared to those younger than
35 years (HR 1.87, 95% CI: 0.54-6.41, P = 0.63).
The Kaplan Meier curves are shown in Figure 2, and
there is a significant difference in survival curves
between the two groups. (P < 0.001) of IDU and non-
I D U .B e c a u s et h et h r e eI D Uw i t ht h el o n g e s tf o l l o wu p
became infected with HCV, the figure gives the impres-
sion that all IDU became infected when in fact only 16
of 39 acquired HCV infection.
In 25 (63%) of the 40 incident cases of HCV, a HCV-
PCR test was performed and 23 (92%) were PCR positive.
Medical records were reviewed for documented evidence
to identify sexual health risks in transmission of HCV in
24 non-injecting HCV seroconvertors. One case reported
fisting, one reported rectal bleeding and one had a penile
ulcer. Two reported they had not practised fisting.
On review of the records, the reason for HCV antibody
testing, in the majority of cases of HCV (83%, n = 33) was
a rise in routinely tested liver enzymes (n = 31), or the
development of symptoms suggesting hepatitis (n = 2).
Seven (18%) asymptomatic cases were identified in routine
screening for HCV and of these two had slightly elevated
aminotransferase levels which were not the reason for the
test. The peak median AST (aspartate aminotransferase)
levels were four times the upper limit of normal (ULN)
(inter quartile range (IQR) 2-8 times) and the peak median
ALT (alanine aminotransferase) levels were seven times
the ULN (IQR 3-18 times) among the 33 who were tested
because of abnormal liver function tests or development
of hepatitis symptoms.
Discussion
Our study is one of the larger cohort studies performed
to date and the first cohort study in Australia, to report
presumed sexual transmission of HCV among HIV-
infected MSM who do not inject drugs. Our study sug-
gests that HIV positive MSM who have never IDU have
a low but significant risk of HCV infection of about half
a percent per year. Our data supports reports from
other studies from the UK [6], Switzerland [7] and
Amsterdam [9] which also report presumed sexual
transmission in about 1 percent of HIV-infected MSM
per year.
Table 1 Population characteristics of the study cohort of HIV positive MSM
Description HCV positives (n = 40) HCV negatives N = 580
Mean age (years) at HIV diagnosis (range) 32(20-45) 34 (17-72)
Mean age (years) at last negative HCV test (range) 39(25-64) 40(20-78)
IDU 16 (40%) 23 (4%)
Australian born 32 (80%) 402 (69%)
Most recent median CD4 cell count cells/mm
3 (Interquartile range) 531(358-856) 568 (404-731)
Most recent HIV viral load <50 (copies/ml) 25 (63%) 311 (54%)
Period of follow up in months
400.00 300.00 200.00 100.00 0.00
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Figure 2 Kaplan-Meier analysis of contraction of Hepatitis C
among HIV positive MSM, comparing IDU and non-IDU. IDU =
injecting drug use. Cum Survival = Cumulative survival. Because the
three IDU with the longest follow up became infected with HCV,
the figure gives the impression that all IDU became infected when
in fact only 16 of 39 acquired HCV infection.
Gamage et al. BMC Infectious Diseases 2011, 11:39
http://www.biomedcentral.com/1471-2334/11/39
Page 3 of 6There are four published cohort studies of the inci-
dence of HCV among HIV-infected MSM without other
recognized HCV risks where it was possible to calculate
an incidence per 100 person years. In the UK [6] a
study of 308 HIV infected MSM with 1190 PY of follow
up reported an incidence of 0.92/100PY. In Switzerland
[ 7 ]as t u d yo f1 5 7 1H I Vi n f e c t e dM S Mw h or e p o r t e d
unsafe sex (n = 414) reported an incidence of 0.7/100PY
(95% CI 0.3-1.4). In Amsterdam [9] a study of 1836
MSM including 504 HIV infected MSM (between years
2000-2003) with 572 PY of follow up reported an inci-
dence of 0.87/100PY (95% CI 0.28-2.03). An Australian
study [10] of 159 HIV infected MSM with 238 PY of
follow up reported no cases of HCV infection although
these findings are consistent with our study because the
upper limit of their 95% confidence interval was 1.54/
100 PY that includes our point estimate of 0.6/100 PY.
There are three published cohort studies of the inci-
dence of HCV among HIV negative MSM without other
recognized HCV risks where it is possible to calculate
an incidence per 100 person years. In the UK [18] a
study of 948 HIV negative MSM who were not IDU,
with 3335 PY of follow up reported an incidence of
0.15/100PY(95% CI 0.05-0.35). In Australia, a study [10]
among 1383 HIV negative MSM with 4412 PY of follow
up reported an incidence of 0.11/100 PY (95% CI 0.03-
0.26) and only one of 5 HCV positives reported injecting
drug use. In Canada a study [19] of 1053 HIV-negative
MSM without other risks for HCV transmission with
2610PY of follow up reported no cases with upper limit
of 95% confidence interval 0.14/100PY.
There are five published studies where it was either
not possible to calculate a specific incidence of HCV
among either HIV-positive or HIV-negative MSM who
were not injecting drugs. In France [8], 4 cases of HCV
occurred in 252 HIV-infected MSM whose follow up
time was not specified although among the entire cohort
of 402 HIV-positives the median follow up of 36 months.
A study with 20 years of data from 12 cohorts in the
CASCADE collaboration [20] 216 cases occurred among
3014 HIV-infected MSM, although data on drug inject-
ing status was not presented. In Germany [21] a study
among MSM with 10199 PY of follow up reported an
incidence of between 0.36-1.05/100 PY although again
the incidence according to drug injecting status was not
presented. A study from Denmark [22] in the 1980s
documented HCV transmission in 250 MSM without
other risks but the HIV prevalence was not given. Simi-
larly an Italian study [23] of 244 MSM without IDU
documented an incidence of 1.37/100 PY, but again
there was no information on HIV prevalence.
The most common reason for HCV testing among
HCV positive individuals in our study was the develop-
ment of abnormal liver function tests. There were seven
cases identified through routine screening for HCV that
only began in 2008 and it is possible that among these
seven cases, infection had occurred significantly earlier.
This bias is evident in the survival curve with the
increase in gradient of the curve at about 200-300
months of follow up, but would have only had a minor
effect on the incidence estimate. The data do however
suggest that routine monitoring of liver function tests
will identify the majority of cases of even asymptomatic
HCV infection. This finding supports a recent study in
the UK [24] where elevated liver enzymes were the most
c o m m o nr e a s o nf o rH C Vd i a g n o s i s .A n o t h e rs t u d y[ 2 5 ]
among HIV positive MSM showed testing for ALT was
more sensitive than HCV antibody testing for early diag-
nosis of HCV. However given the importance of early
treatment of HCV diagnosis, clinicians should not rely
only on elevations of routine liver function tests because
they will miss a significant minority of cases.
Routine testing for hepatitis C among MSM began in
2008 [17] and since then, of the 444 HIV-positive HCV-
negative MSM who were having bloods drawn at least
once a year at our clinic, 75% (n = 332) had subsequent
HCV serology. It would be helpful to put the rates of
Hepatitis C infection described in our study in context
with the rates of other STI in MSM in Victoria. In a
study looking at the proportion of samples positive for
gonorrhoea and chlamydia by anatomical site between
2002 to 2009 at our centre in MSM, no increase in
either infection was noted however there was a sugges-
tion that the proportion of samples positive for gonor-
rhoea may be falling (Vodstrcil LA, Fairley CK, Fehler
G, Leslie D, Walker J, Bradshaw C, Hocking JS: Trends
in Chlamydia and Gonorrhoea Positivity among Hetero-
sexual Men and Men who have sex with Men attending
a sexual health service between 2002 and 2009, sub-
mitted). In contrast rates of syphilis have risen signifi-
cantly over this time in MSM [26,27]. The first case of
anorectal LGV was detected in a MSM, Victoria in 2005
[28] and since then 18 have been diagnosed in MSM
with HIV at MSHC until March 2010.
Our study had a number of weaknesses. Firstly it was
retrospective and therefore excluded some individuals
from the analysis who were either never tested for HCV
and were HCV positive when first tested. If the incidence
of HCV among those never tested was very high then we
would have underestimated the true incidence. Conver-
sely if the HCV incidence among those never tested was
very low then we would have overestimated the true inci-
dence. Our estimate would have also underestimated the
true incidence if a significant proportion of those whose
first HCV test was positive were true incident cases. If we
included all of the 41 cases positive on their first tests it
would have only increased the incidence among MSM
who were non-IDU from about 0.6/100 PY to 1.7 per 100
Gamage et al. BMC Infectious Diseases 2011, 11:39
http://www.biomedcentral.com/1471-2334/11/39
Page 4 of 6PY. Given that the objective was to compare the inci-
dence rates between members of the HIV positive MSM
cohort who did and did not engage in IDU, we thought
underestimating the incidence was preferred.
Our study did not collect detailed risk factor informa-
tion prospectively on all members of the cohort and
therefore this information may be incomplete, particu-
larly in relation to the possible risk factors for sexual
transmission of HCV infection. We are therefore unable
to look at hazard ratios for different sexual exposures
(e.g. fisting) in our study. However analysis of sexual
risk was not the primary aim of the study and is an
acknowledged weakness although other investigators
have reported that unprotected traumatic anal sex,
bleeding during sex, fingering, fisting, rimming, and
number of recent sexual partners are risks for possible
sexual transmission [6,7,29].
Under-reporting of IDU may have also biased our
study. Previous studies in Australia have shown however
the social desirability bias (e.g. under reporting of IDU)
is uncommon in Australia compared to the US or UK
[30,31]. Furthermore those who tested positive for HCV
had generally been attending the centre’s service and
seeing the same clinician for years (mean attendance 5
years) and were therefore likely to have established good
rapport with their clinicians.
Conclusions
A considerable proportion of HIV positive MSM who
did not use intravenous drugs contracted HCV, presum-
ably via sexual transmission and the majority was inves-
tigated for HCV because of abnormal liver enzymes.
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